doi:10.19982/j.issn.1000-6621.20220174

Abstract

CLC Number:

R978.3
R81

Figures/Tables 2

References 12

[1]	李洁琼, 申阿东. 儿童结核病诊断进展及存在的问题. 中华实用儿科临床杂志, 2019, 34(9):655-659. doi: 10.3760/cma.j.issn.2095-428X.2019.09.005. doi: 10.3760/cma.j.issn.2095-428X.2019.09.005
[2]	Reuter A, Hughes J, Furin J. Challenges and controversies in childhood tuberculosis. Lancet, 2019, 394(10202):967-978. doi: 10.1016/S0140-6736(19)32045-8. doi: S0140-6736(19)32045-8 pmid: 31526740
[3]	Tao NN, He XC, Zhang XX, et al. Drug-Resistant Tuberculosis among Children, China, 2006-2015. Emerg Infect Dis, 2017, 23(11):1800-1805. doi: 10.3201/eid2311.170234. doi: 10.3201/eid2311.170234 URL
[4]	杨丹丹. 儿童耐药结核病诊治进展. 国际儿科学杂志, 2022, 49(2):109-113. doi: 10.3760/cma.j.issn.1673-4408.2022.02.009. doi: 10.3760/cma.j.issn.1673-4408.2022.02.009
[5]	廖琼, 谭珊, 朱渝, 等. 儿童耐药结核病的临床特点及二线抗结核治疗效果分析. 中华儿科杂志, 2017, 55(2):100-103. doi: 10.3760/cma.j.issn.0578-1310.2017.02.010. doi: 10.3760/cma.j.issn.0578-1310.2017.02.010
[6]	李静, 詹学. 儿童淋巴结结核的诊断与治疗. 中华临床医师杂志(电子版), 2013, 7(15):7153-7157. doi: 10.3969/cma.j.issn.1674-0785.2013.15.087. doi: 10.3969/cma.j.issn.1674-0785.2013.15.087
[7]	Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother, 2014, 48(1):107-115. doi: 10.1177/1060028013504087. doi: 10.1177/1060028013504087 pmid: 24259600
[8]	World Health Organization. Rapid communication: key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva:World Health Organization, 2018.
[9]	World Health Organization. WHO consolidated guidelines on tuberculosis, Module 4: Treatment- Drug-resistant tuberculosis treatment. Geneva:World Health Organization, 2020.
[10]	谢莉, 高静韬. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响. 中国防痨杂志, 2020, 42(7):687-694. doi: 10.3969/j.issn.1000-6621.2020.07.009. doi: 10.3969/j.issn.1000-6621.2020.07.009
[11]	谢莉, 朱慧, 高静韬, 等. 贝达喹啉血药浓度在耐药肺结核治疗中的变化及其与QTc间期延长的相关性. 中国防痨杂志, 2022, 44(3):219-226. doi: 10.19982/j.issn.1000-6621.20210696. doi: 10.19982/j.issn.1000-6621.20210696
[12]	中华医学会结核病学分会儿童结核病专业委员会, 中国研究型医院学会结核病学专业委员会, 国家呼吸系统疾病临床医学研究中心, 等. 儿童肺结核诊断专家共识. 中华实用儿科临床杂志, 2022, 37(7):490-496. doi: 10.3760/cma.j.cn101070-20211207-01436. doi: 10.3760/cma.j.cn101070-20211207-01436

[1]	. [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 527-530.
[2]	Wang Xueyu, Wang Yujin, Chu Naihui, Kang Wanli, Nie Wenjuan. A preliminary study on the enhanced in vivo exposure of sudapyridine in Mycobacterium abscessus-infected rats with the co-administration of clofazimine or clarithromycin [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 150-157.
[3]	. [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1410-1413.
[4]	Yang Zhenggui, Jiang Zeshun, Liu Lan, Han Xue. Effect of Mycobacterium vaccinae on T Lymphocyte subsets in peripheral blood of HIV patients complicated with latent Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2023, 45(10): 925-931.
[5]	Peng Jiangli, Chen Jie, Chen Yonggang, Wang Lu, Li Na, Luo Ji, Han Yi, Yu Mingli, Zhu Jiangchun. SLC22A12 gene polymorphism study on susceptibility to hyperuricemia induced by pyrazinamide [J]. Chinese Journal of Antituberculosis, 2023, 45(2): 151-158.
[6]	Wang Honghong, Guo Shaochen, Zhou Wenqiang, Liu Zhongquan, Zhu Hui, Lu Yu. Influence of linezolid blood concentration on hematological toxicity in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2023, 45(2): 165-171.
[7]	Yao Rong, Lu Yu. Research progress on the drug resistance and mechanism of the anti-tuberculosis drug bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 973-977.
[8]	NIE Wen-juan, ZHOU Wen-qiang, CHU Nai-hui. Research progress on pharmacokinetics and drug interaction of bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 716-719.
[9]	LU Ni-hong, SHEN Ling-jun, LIU Hong-lu, CHEN Yang-jun, YANG Yan, DU Ying-rong. Clinical value of ESAT-6, immune and inflammatory indexes in the diagnosis of anti-tuberculosis drug-induced liver injury [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 654-659.
[10]	LIANG Li, ZOU Li-ping, XIE Fang-hui, CHEN Qing, WU Gui-hui. Three cases of anti-tuberculosis therapy-associated acute liver failure in tuberculosis children and literature review [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 343-348.
[11]	XIE Li, ZHU Hui, GAO Jing-tao, LIU Zhong-quan, MA Li-ping, ZHANG Li-qun, GE Qi-ping, NIE Li-hui, KONG Zhong-shun, WU Xiao-guang, LIU Rong-mei, CHEN Hong-mei, SONG Yan-hua, LI Qiang, LYU Zi-zheng, LIU Yu-hong, LU Yu, PANG Yu, GAO Meng-qiu. Changes of plasma concentration of bedaquiline during the treatment of drug-resistant pulmonary tuberculosis and its assocation with QTc interval prolongation [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 219-226.
[12]	LU Ni-hong, SHEN Ling-jun, LIU Hong-lu, CHEN Yang-jun, DU Ying-rong. Analysis of correlation between the level of matrix metalloproteinases and anti-tuberculosis drug-induced liver injury [J]. Chinese Journal of Antituberculosis, 2022, 44(2): 164-168.
[13]	Chinese Antituberculosis Association , National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention . Recommendations on pretomanid (PA-824) in the treatment of multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 38-44.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 12

Related Articles 13

Recommended Articles

Metrics

Comments